Label for post-surgical Sutent on a knife edge, as competition in first-line closes in

21 September 2017

First approved in the USA in 2006, Sutent (sunitinib) has brought in over a billion dollars for Pfizer (NYSE: PFE) every year since 2010, including last year, thanks to its broad use as a first-line kidney cancer therapy.

There are signs, however, that a slight sales wobble - $279 million last quarter, compared with $285 million for third-quarter 2016 - could be more just a mere bump in the road.

Now, as the US Food and Drug Administration's advisory panel says it’s evenly split on the value of Sutent in the adjuvant setting, Pfizer’s effort to broaden the drug’s use may be about to falter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK